New Drug Approvals Archive - May 2015
New Indication Approved: May 8, 2015
Treximet (sumatriptan succinate and naproxen sodium)
Patient Population Altered: May 15, 2015
Invega Trinza (paliperidone palmitate) Extended-Release Injectable Suspension
Date of Approval: May 18, 2015
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Schizophrenia
Invega Trinza (3-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia.
Stiolto Respimat (olodaterol and tiotropium) Inhalation Spray
Date of Approval: May 21, 2015
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Chronic Obstructive Pulmonary Disease
Stiolto Respimat (olodaterol and tiotropium bromide) is a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).
Viberzi (eluxadoline) Tablets
Date of Approval: May 27, 2015
Company: Allergan, Inc.
Treatment for: Irritable Bowel Syndrome
Viberzi (eluxadoline) is a mu-opioid receptor agonist indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Read more: Viberzi (eluxadoline) FDA Approval History
New Indication Approved: May 27, 2015
- FDA Approves Xifaxan (rifaximin) for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)
Read more: Xifaxan (rifaximin) FDA Approval History
New Indication Approved: May 28, 2015
Treatment for: Lymphangioleiomyomatosis